Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
38 hedge funds and large institutions have $89.9M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
3% more funds holding
Funds holding: 37 → 38 (+1)
23% less capital invested
Capital invested by funds: $116M → $89.9M (-$26.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.55M |
| 2 |
NEPWA
New England Private Wealth Advisors
Wellesley,
Massachusetts
|
+$1.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.49M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$348K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$347K |
| 2 |
Goldman Sachs
New York
|
-$279K |
| 3 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$275K |
| 4 |
Barclays
London,
United Kingdom
|
-$143K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$68.4K |
ELOX Hedge Fund Activity: Q4 2018 in Review
38 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q4 2018, worth a combined $89.9M — down 23% from $116M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ELOX positions and 3 closed out — a net gain of 1 holder — while 14 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $5.55M. The largest seller was Deutsche Bank, cutting an estimated $347K.
- 38 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q4 2018, up from 37 in Q3 2018.
- Funds reported $89.9M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 23% quarter-over-quarter.
- 4 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 3 closed out, a net change of +1 holder.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was BlackRock, an estimated $5.55M added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Deutsche Bank, an estimated $347K sold.
Based on aggregated 13F filings for Q4 2018.